News Release 

Staging β-amyloid pathology with amyloid positron emission tomography

JAMA Neurology

What The Study Did: This multicenter study used in vivo β-amyloid cerebrospinal fluid, a biomarker of Alzheimer disease, and positron emission tomography findings to track progression of Alzheimer disease over six years among study participants.

Authors: Niklas Mattsson, M.D., Ph.D., and Oskar Hansson, M.D., Ph.D., of Lund University in Malmo, Sweden, are the corresponding authors.

(doi:10.1001/jamaneurol.2019.2214)

Editor's Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

###

Media Advisory: This article is being released to coincide with the Alzheimer's Association International Conference. The full study and related articles also being released to coincide with the event are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time: https://jamanetwork.com/journals/jamaneurology/fullarticle/2738356?guestAccessKey=76eb6e58-8821-46cf-978a-2d91f3251e16&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=071719

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.